Revvity (RVTY)
NYSEHealth CareDiagnostics & ResearchSnapshot 2026-07-07
$112.08-0.77%
Close 2026-07-07 · 1-day change
Reading RVTY? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track RVTY free→NYSEHealth CareDiagnostics & ResearchSnapshot 2026-07-07
Reading RVTY? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track RVTY free→A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This investment represents a stable growth opportunity in the healthcare sector. The current thesis state is intact, supported by strong recent financial performance, though management has mixed priorities that could impact future growth.
The market currently prices RVTY at a premium compared to its peers, indicating that investors have high expectations for its performance. However, the valuation is considered stretched, suggesting that any negative news could lead to a significant reassessment.
Management aims for organic revenue growth of 3%-4% for 2026, and recent results show progress towards this goal. However, the adjusted earnings per share target has been adjusted downward, indicating some uncertainty in achieving full-year targets.
The long-term thesis hinges on the performance of sector bellwethers like TMO, DHR, and IDXX. If these companies continue to perform well, RVTY could benefit, but any negative guidance from them could pose risks to RVTY's momentum.
In the next 1 to 3 years, RVTY's performance will depend on both its internal execution and the broader healthcare sector dynamics. Not investment advice.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports this improvement. There are no new threats to the thesis. Recent financial performance remains strong, which is a positive sign.
as of 2026-07-07
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: Earnings results will show Revvity's financial health and progress toward goals.
Confirms one read:Q2 2026 earnings show revenue growth of 7% or more.
Confirms the other:Q2 2026 earnings show revenue growth below 5%.
Why it matters: A miss raises worries about Revvity's growth and market position.
Confirms:Q2 2026 earnings report shows revenue below $740 million.
Disproves:Q2 2026 earnings report shows revenue above $740 million.
Why it matters: Lower organic growth shows market problems. This can hurt investor confidence.
Confirms:Organic revenue growth was below 2% for 2026.
Disproves:Organic revenue growth meets or exceeds 3% for 2026.
Why it matters: Hitting this growth target shows strong operations and demand in the market.
Confirms:Organic revenue growth reported at 3% or higher in Q2 2026.
Disproves:Organic revenue growth reported below 2% in Q2 2026.
Why it matters: Hitting or exceeding this goal shows strong profits. It also shows efficient operations.
Confirms:Adjusted EPS reported at $5.35 or higher in Q2 2026.
Disproves:Adjusted EPS reported below $5.20 in Q2 2026.
Why it matters: This divestiture is key for Revvity's focus on core operations and growth. It may improve margins and streamline operations.
Confirms:A definitive agreement is signed for the divestiture by the end of Q2 2026.
Disproves:The divestiture is delayed beyond the expected timeline or fails to close.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.